GSK Closed the Nuvalent Deal on 15 July. Seven Days Later, the FDA Approved the Drug.
GSK closed its Nuvalent acquisition on 15 July. The FDA approved Jideytro on 22 July, two months ahead of schedule, making it GSK’s first lung cancer drug.
NSCLC
GSK closed its Nuvalent acquisition on 15 July. The FDA approved Jideytro on 22 July, two months ahead of schedule, making it GSK’s first lung cancer drug.